Righton Gene announced on April 9 that in 2022, the company achieved operating revenue of CNY 424 million, up 45.83% year-on-year; attributable net profit of CNY 40,473,600, down 14.49% year-on-year; basic earnings per share of CNY 0.73.

The US Department of Health and Human Services' Biomedical Advanced Research Development Authority (BARDA) this week issued a solicitation for proposals for the research and development of immune assays to evaluate responses to COVID-19 vaccines.

​​Magtivio, a magnetic bead manufacturer from The Netherlands announces a distribution agreement with Premedical Lab from Beijing, China, a professional laboratory products distribution company in the life sciences arena.

According to Kalorama Information, the U.S. IVD market reached $53 billion in 2022, or approximately 40% to 45% of the global market. Projected growth is 2.4% annually on average through 2027.

The 8th Experimental Medicine Conference of China is scheduled to be held at Primus Hotel Nanchang International Expo City on 27 May in 2023.

The 10th IVD Industry Development Conference of China is scheduled to be held at Primus Hotel Nanchang International Expo City from May 28 to 29 in 2023.

On March 21, according to the Qichacha data, the major shareholders of Shenzhen Thistory Bio-Medical Company have been changed from Shenzhen Thistory Bio-medical Management and Consulting Enterprise to Zybio Inc.

In March 2023, Cygnus received another round of Series C+ financing of hundreds of millions of RMB, led by Source Capital, and followed by Jianxin Equity, Yizhuang State Investment, Fangzhenghesheng, and Hetang Venture Capital.

DiaSorin said late Friday that it has nabbed US Food and Drug Administration 510(k) clearance for a molecular assay that differentiates between infections with the SARS-CoV-2 and influenza A and B viruses.

Cue Health announced on Monday that it has received Emergency Use Authorization from the US Food and Drug Administration for its molecular monkeypox test.